Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 15/20 | 0.51 |
| ▸ | VCP | P55072 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22520618 | 0.93 | NPC1 (0.56) | NPC1HRH3VCP | |
| SCHEMBL18389833 | 0.88 | NPC1 (0.58) | NPC1HRH3VCP | |
| SCHEMBL25571582 | 0.86 | NPC1 (0.64) | NPC1HRH3VCPTP53 | |
| SCHEMBL26949128 | 0.85 | NPC1 (0.47) | NPC1HRH3VCP | |
| SCHEMBL24475400 | 0.84 | NPC1 (0.50) | NPC1HRH3VCP | |
| SCHEMBL13741291 | 0.84 | HRH3 (0.51) | NPC1HRH3VCP | |
| SCHEMBL27013338 | 0.84 | NPC1 (0.50) | NPC1HRH3VCP | |
| SCHEMBL24233184 | 0.84 | NPC1 (0.46) | NPC1HRH3VCP | |
| SCHEMBL18713115 | 0.84 | NPC1 (0.67) | NPC1HRH3TP53 | |
| SCHEMBL24475383 | 0.83 | NPC1 (0.44) | NPC1HRH3VCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018123-A1 | COMPOUND FOR INHIBITING OR DISINTEGRATING ANDROGEN RECEPTOR, AND PHARMACEUTICAL USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2024-01-18 | — | — | US | disclosed |
| US-20230398117-A1 | 3-hydroxy-N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide Derivatives | NOVARTIS AG (CH) | 2023-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230398117-A1 | 3-hydroxy-N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide Derivatives | PAH, PKD1, REN | NPC1 191/4885HRH3 531/4885VCP 3714/4885 |
| US-20240018123-A1 | COMPOUND FOR INHIBITING OR DISINTEGRATING ANDROGEN RECEPTOR, AND PHARMACEUTICAL USE THEREOF | AR, NR5A1, SHBG | NPC1 477/4885HRH3 2037/4885VCP 1096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.